Xencor price target raised to $42 from $40 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Xencor (XNCR) to $42 from $40 and keeps an Overweight rating on the shares. By this time next year, Cantor expects Xencor could have a recommended Phase 3 dose identified for two different T-cell engage antibodies, with Phase 3s both starting in 2027, as well as a Phase 2b UC study of long-acting TL1A antibody ‘942 largely or even fully enrolled, the analyst tells investors in a research note.